Telmisartan And Amlodipine Tablet
FDA Recall NDC 0378-1075

Latest: Class III · Status: Ongoing · Initiated Oct 01, 2026 · 1 enforcement report

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Telmisartan And Amlodipine (NDC 0378-1075). A significant event, classified as Class III, was initiated on Oct 01, 2026 by Mylan Pharmaceuticals Inc.. The reported reason for this action was: "Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications"

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

October 2026 Class III Recall: Superpotent Drug

Recall Number
Class III Ongoing
Reason for Recall
Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications
Initiated
Oct 01, 2026
Reported
Oct 28, 2026
Quantity
21,620 30-count bottles

Recall Profile & Regulatory Data

Event ID
100048
Classification
Class III
Enforcement Status
Ongoing
Recalling Firm
Viatris, Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the USA.
Product Description
Telmisartan and Amlodipine, Tablets, USP, 40mg/5 mg, 30-count Bottle, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA, Made in India, NDC 0378-1075-93.
Batch or Lot Expiration Information
Lot# 3228113, 3228114, 3228115, Exp Date: Oct 31, 2026
Lot# 3228120, 3228121, Exp Date: Nov 30, 2026.
Affected Packages Involved in this Recall
0378-1075-93Telmisartan And Amlodipine
0378-1076-93Telmisartan And Amlodipine
0378-1077-93Telmisartan And Amlodipine
0378-1078-93Telmisartan And Amlodipine

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.